Liver Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Liver Cancer stocks.

Liver Cancer Stocks Recent News

Date Stock Title
Nov 1 ALNY Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
Nov 1 ALNY Alnylam Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Nov 1 ALNY Alnylam Pharmaceuticals Inc (ALNY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Nov 1 ALNY Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight
Nov 1 ALNY Q3 2024 Alnylam Pharmaceuticals Inc Earnings Call
Oct 31 ALNY Alnylam Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
Oct 31 ALNY Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
Oct 31 ALNY Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say
Oct 31 ALNY Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Lags Revenue Estimates
Oct 31 ALNY Alnylam: Q3 Earnings Snapshot
Oct 31 ALNY Alnylam Pharmaceuticals Non-GAAP EPS of -$0.50 misses by $0.11, revenue of $500.92M misses by $26.1M
Oct 31 ALNY Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
Oct 30 ALNY Alnylam Pharmaceuticals Q3 2024 Earnings Preview
Oct 30 ALNY Cognizant signs deal to enhance Alnylam’s IT infrastructure
Oct 30 ALNY Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024
Oct 30 SHPH Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Oct 30 SHPH Shuttle Pharmaceuticals dips 6%, prices $4.5M share offering
Oct 30 SHPH Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Oct 29 SHPH Shuttle Pharma Pays Off Senior Secured Convertible Note
Oct 29 SHPH Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Liver Cancer

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults, and is the most common cause of death in people with cirrhosis.It occurs in the setting of chronic liver inflammation, and is most closely linked to chronic viral hepatitis infection (hepatitis B or C) or exposure to toxins such as alcohol or aflatoxin. Certain diseases, such as hemochromatosis and alpha 1-antitrypsin deficiency, markedly increase the risk of developing HCC. Metabolic syndrome and NASH are also increasingly recognized as risk factors for HCC.As with any cancer, the treatment and prognosis of HCC vary depending on the specifics of tumor histology, size, how far the cancer has spread, and overall health.
The vast majority of HCC occurs in Asia and sub-Saharan Africa, in countries where hepatitis B infection is endemic and many are infected from birth. The incidence of HCC in the United States and other developing countries is increasing due to an increase in hepatitis C virus infections. It is more common in males than females for unknown reasons.

Browse All Tags